It is generally believed, higher the per-capita expenditure of healthcare, better is the overall ‘healthcare performance’ of a nation. However, this myth has recently been busted by a new study, the take-home message of which would be quite relevant for … Continue reading
Tag Archives: BRIC
RHDS: A Simmering Promise in Despondency
Eric Topol, a leading cardiologist who has embraced the study of genomics and the latest advances in technology to treat chronic disease says, “We’ll soon use our smartphones to monitor our vital signs and chronic conditions in future.” By clicking … Continue reading
Access to Medicine: Losing Track in Cacophony
Indian Healthcare space is by and large an arena, where perceptions prevail over the changing reality in many important areas. Consequently, fierce discourse in those areas mostly gives rise to a cacophony of ‘Your Perceptions Against Mine’. It is intriguing, why even … Continue reading
Pharma FDI: Damning Report of Parliamentary Panel, PM Vetoes…and Avoids Ruffling Feathers?
An interesting situation emerged last week. The Parliamentary Standing Committee (PSC) on Commerce proposed a blanket ban on all FDI in brownfield pharma sector. Just two days after that, the Prime Minister of India vetoed the joint opposition of the Department … Continue reading
A Force Multiplier: An “Armageddon”: A Contender for Supremacy in the Generic Pharma World
It is very important for any country to ensure access to most appropriate medicines for the patients as and when they require. In many disease areas such access can be remarkably improved through affordable generic drugs, which offer significant savings … Continue reading
Government Ups the Ante for More Compulsory Licenses in India
On January 12, 2013, one of the leading dailies of India first reported that in a move that is intended to benefit thousands of cancer patients, Indian Government has started the process of issuing Compulsory Licenses (CL) for three commonly … Continue reading
The traditional ‘Business Models’ of R&D focused Global Pharmaceutical majors are undergoing a metamorphosis
Mounting pressure on the P&L account, as the products go off patent: Patented new products are the prime growth driver of the research based pharmaceutical companies of the world. Since last few years, because of various reasons, the number of … Continue reading